Abstract:Hutter et al.1 first reported that a bone marrow transplant using stem cells derived from a donor with homozygous CCR5 delta32 gene mutation remained HIV-positive but virus-free (below the limits of detection) after halting antiretroviral therapy. Since this observation in 2009, mutation of the CCR5 gene has become an important target in the prevention and treatment of HIV infection. The CRISPR-Cas9 system, which has been called the biggest biotech discovery in the history of molecular biology, can be used for precise genome engineering with the aim of treating genetic disorders. Currently, the application of gene-editing tools, such as CRISPR-Cas9, for genetic engineering of embryos for use in assisted reproduction is prohibited in much of Europe, the United States, and China.2,3 However, at the Second International Summit on Human Genome Editing in Hong Kong (http://www.nationalacademies.org/), Jiankui He claimed that his team had used CRISPR-Cas9 systems to successfully edit the CCR5 gene in twin baby girls, Lulu and Nana. In Lulu, one copy of exon 3 in the CCR5 gene has an inserted base, with the other copy missing four bases. In Nana, a 15-nucleotide deletion (delta15) within one copy of CCR5 was described, with the other copy of the CCR5 gene remaining intact. The CCR5 gene is located at chromosome region 3p21.314 and comprises three exons, two introns and two promoters.5 The C-C chemokine receptor 5 (CCR5) protein encoded by the CCR5 gene consists of 352 amino acids6 and is composed of a conserved, N-terminal seven trans-membrane domain and a C-terminal tail.7 This structure is important for the binding of HIV glycoprotein receptors to host cells and HIV co-receptor CD4 activity.8 Samson et al. found that the second extracellular loop of CCR5 is specifically affected by delta32 mutations in exon 3, which result in the absence of the final three trans-membrane domains in addition to regions involved in G-protein interaction and signal transduction. In CD4+ cells, this mutation inhibits CCR5 protein expression on the cell surface, thereby preventing HIV envelope fusion.9 Moreover, the presence of the mutant delta32 protein in the endoplasmic reticulum inhibits transport of the wild-type CCR5 protein to the cell surface via a trans-dominant mechanism.10 Because most strains of HIV use CCR5 to enter host cells, the deletion of both copies of the CCR5 gene (not one copy) protects against HIV infection.11,12 Thus, Nana would still be susceptible to HIV infection. Although He demonstrated that Lulu was homozygous for the disrupted CCR5 gene, this child may also be genetically mosaic, which means that Lulu may carry some edited cells and some unedited cells. Furthermore, although He claimed an absence of dangerous off-target mutations in both twins based on single cell sequencing studies, these results were not peer-reviewed and confirmed by an independent team. Therefore, Lulu’s genetic status should be continually monitored throughout her life, and it is possible that she may encounter unpredictable disorders in the future. Role of CCR5 deficiency in diseases Individuals who are naturally homozygous for the delta32 mutation, which abolishes CCR5 expression, are generally healthy and at no apparent disadvantage.8 However, apart from the protective effects against HIV infection, the impacts of this mutation, positive or negative, on other diseases are open to debate.13 To date, several studies have indicated that CCR5 delta32 mutations provide significant resistance to smallpox,14 in addition to enhancing certain forms of memory15 but also render individuals more vulnerable to influenza16 and the West Nile virus.17 In mice, CCR5 deficiency exacerbates stroke-related brain injury.18 CCR5 is thought to mediate pro-inflammatory effects in the pathogenesis of rheumatoid arthritis (RA).19 However, Fleishaker et al.20 reported that a CCR5 antagonist (maraviroc), which has been approved for use in HIV patients, was ineffective in treating patients with RA who had not responded to methotrexate (MTX). Moreover, a double-blind, placebo-controlled trial in 2015 found that maraviroc was associated with reduced bone loss at the hip and lumbar spine of HIV-infected patients.21 Other studies demonstrated direct roles of CCR5 in osteoclastogenesis and osteoclast-osteoblast communication.22,23 These clinical and basic investigations highlight the skeletal effects associated with the functional loss of CCR5.24

Could the CCR5-Δ32 Mutation be Protective in SARS-CoV-2 Infection?

A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation

The Role Of A Mutant Ccr5 Allele In Hiv-1 Transmission And Disease Progression

Investigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population

Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.

Genetic Influence of<i>CCR5, CCR2,</i>and<i>SDF1</i>Variants on Human Immunodeficiency Virus 1 (HIV‐1)–Related Disease Progression and Neurological Impairment, in Children with Symptomatic HIV‐1 Infection

Association of the CCR5Δ32 polymorphism and its ligand RANTES-403G/A polymorphism with coronary artery disease: a meta-analysis.

Effect Of Ccr5-Delta 32 Heterozygosity On Hiv-1 Susceptibility: A Meta-Analysis

CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair

Host genetic variants regulates CCR5 expression on immune cells: a study in people living with HIV and healthy controls

Impact of CCR5Δ32 on the risk of infection, Staphylococcus aureus carriage, and plasma concentrations of chemokines in Danish blood donors

The Potential Risks of C-C Chemokine Receptor 5-Edited Babies in Bone Development

Distribution of CCR5delta32 in human immunodeficiency virus-infected children and its relationship to disease course.

The single nucleotide polymorphism rs4986790 (c.896A>G) in the gene TLR4 as a protective factor in corona virus disease 2019 (COVID-19)

The genetic associations and epistatic effects of the CCR5 promoter and CCR2-V64I polymorphisms on susceptibility to HIV-1 infection in a Northern Han Chinese population.

Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?

CCR5 Editing by Staphylococcus Aureus Cas9 in Human Primary CD4+ T Cells and Hematopoietic Stem/progenitor Cells Promotes HIV-1 Resistance and CD4+ T Cell Enrichment in Humanized Mice

Intra- and Interspecific Variation of the CCR5 Gene in Higher Primates.

Linkage of the CCR5Δ32 Mutation with a Functional Polymorphism of CD45RA

Association Between The Ccr2-Val64ile Polymorphism And Susceptibility To Hiv-1 Infection: A Meta-Analysis

Possible Impact of 190G > A CCR2 and Δ32 CCR5 Mutations on Decrease of the HBV Vaccine Immunogenicity—A Preliminary Report